Nifty
:
24353.55
Sensex
:
78493.54
156.80 (0.65%)
504.86 (0.65%)
Nifty
Sensex
:
:
24353.55
78493.54
156.80 (0.65%)
504.86 (0.65%)

Aurobindo Pharma Ltd.

Pharmaceuticals & Drugs - Global

Rating :
73/99

BSE: 524804 | NSE: AUROPHARMA

NSE BSE
1386.00
17-Apr-2026
  • Open
  • High
  • Low
  • Previous Close
  •  1388.9
  •  1394.9
  •  1375.3
  •  1386.50
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1612415
  •  2234775090.3
  •  1394.9
  •  1016.1

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 80,478.78
  • 23.08
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 79,066.27
  • N/A
  • 2.24

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 51.82%
  • 0.58%
  • 5.74%
  • FII
  • DII
  • Others
  • 15.24%
  • 22.84%
  • 3.78%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.68
  • 5.07
  • 8.47

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.52
  • 4.30
  • 12.10

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.58
  • -8.16
  • 21.84

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.99
  • 18.88
  • 21.13

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.22
  • 1.91
  • 2.12

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 9.59
  • 9.29
  • 10.51

Earnings Forecasts:

(Updated: 18-04-2026)
Description
2024
2025
2026
2027
Adj EPS
60.02
62.04
76.54
87.02
P/E Ratio
23.09
22.34
18.11
15.93
Revenue
31378.1
33545.5
38003.7
41072.1
EBITDA
6582.79
6853.25
7909.8
8744.22
Net Income
3485.88
3607.21
4513.68
5137.68
ROA
7.35
7.14
8.37
8.66
P/B Ratio
2.47
2.26
2.04
1.83
ROE
11.16
10.46
11.81
12.03
FCFF
1883.81
2454.38
2340.7
3691.64
FCFF Yield
2.43
3.17
3.02
4.76
Net Debt
-75.93
-1759.09
-4195.09
-6824.63
BVPS
562.21
612.72
680.51
757.87

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Net Sales
8,645.90
7,978.52
8.36%
8,285.70
7,796.07
6.28%
7,868.14
7,567.02
3.98%
8,382.12
7,580.15
10.58%
Expenses
6,872.56
6,400.54
7.37%
6,607.60
6,229.93
6.06%
6,265.11
5,947.45
5.34%
6,590.20
5,907.34
11.56%
EBITDA
1,773.34
1,577.98
12.38%
1,678.10
1,566.14
7.15%
1,603.03
1,619.57
-1.02%
1,791.92
1,672.81
7.12%
EBIDTM
20.51%
19.78%
20.25%
20.09%
20.37%
21.40%
21.38%
22.07%
Other Income
187.64
157.29
19.30%
120.59
136.00
-11.33%
105.30
220.93
-52.34%
134.81
135.62
-0.60%
Interest
92.77
118.48
-21.70%
95.24
112.70
-15.49%
97.75
111.04
-11.97%
115.02
89.43
28.61%
Depreciation
464.73
418.53
11.04%
429.19
382.28
12.27%
405.70
404.18
0.38%
444.43
354.33
25.43%
PBT
1,338.15
1,198.26
11.67%
1,274.26
1,207.16
5.56%
1,204.88
1,325.28
-9.08%
1,367.28
1,242.56
10.04%
Tax
428.72
354.28
21.01%
427.79
390.51
9.55%
382.60
405.67
-5.69%
432.26
322.55
34.01%
PAT
909.43
843.98
7.75%
846.47
816.65
3.65%
822.28
919.61
-10.58%
935.02
920.01
1.63%
PATM
10.52%
10.58%
10.22%
10.48%
10.45%
12.15%
11.15%
12.14%
EPS
15.67
14.56
7.62%
14.61
14.07
3.84%
14.20
15.69
-9.50%
15.56
15.51
0.32%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
33,181.86
31,723.73
29,001.87
24,855.38
23,455.49
24,774.62
23,098.51
19,563.55
16,463.03
14,909.54
13,794.65
Net Sales Growth
7.31%
9.39%
16.68%
5.97%
-5.32%
7.26%
18.07%
18.83%
10.42%
8.08%
 
Cost Of Goods Sold
13,487.17
11,671.89
11,348.78
10,190.48
9,238.91
8,827.71
8,720.74
7,886.32
6,085.55
5,911.00
5,612.30
Gross Profit
19,694.69
20,051.84
17,653.09
14,664.90
14,216.58
15,946.91
14,377.77
11,677.23
10,377.48
8,998.54
8,182.35
GP Margin
59.35%
63.21%
60.87%
59.00%
60.61%
64.37%
62.25%
59.69%
63.04%
60.35%
59.32%
Total Expenditure
26,335.47
25,140.94
23,158.87
21,136.74
19,070.95
19,441.22
18,234.20
15,611.61
12,691.28
11,475.26
10,606.53
Power & Fuel Cost
-
1,012.25
826.03
842.63
626.86
589.28
587.68
556.79
470.95
437.14
419.26
% Of Sales
-
3.19%
2.85%
3.39%
2.67%
2.38%
2.54%
2.85%
2.86%
2.93%
3.04%
Employee Cost
-
4,475.62
3,922.94
3,522.25
3,450.92
3,535.02
3,219.18
2,584.87
2,130.84
1,767.76
1,542.62
% Of Sales
-
14.11%
13.53%
14.17%
14.71%
14.27%
13.94%
13.21%
12.94%
11.86%
11.18%
Manufacturing Exp.
-
3,556.25
3,191.71
2,810.03
2,502.98
2,875.39
2,331.41
2,037.95
1,611.12
1,309.64
1,256.18
% Of Sales
-
11.21%
11.01%
11.31%
10.67%
11.61%
10.09%
10.42%
9.79%
8.78%
9.11%
General & Admin Exp.
-
1,551.60
1,483.77
1,386.66
1,335.03
1,473.59
1,320.69
1,006.68
1,068.22
997.32
686.38
% Of Sales
-
4.89%
5.12%
5.58%
5.69%
5.95%
5.72%
5.15%
6.49%
6.69%
4.98%
Selling & Distn. Exp.
-
2,185.06
1,684.72
1,685.76
1,496.67
1,564.17
1,524.75
1,125.76
1,025.85
848.43
877.14
% Of Sales
-
6.89%
5.81%
6.78%
6.38%
6.31%
6.60%
5.75%
6.23%
5.69%
6.36%
Miscellaneous Exp.
-
688.27
700.92
698.93
419.58
576.06
529.75
413.24
298.75
203.97
877.14
% Of Sales
-
2.17%
2.42%
2.81%
1.79%
2.33%
2.29%
2.11%
1.81%
1.37%
1.54%
EBITDA
6,846.39
6,582.79
5,843.00
3,718.64
4,384.54
5,333.40
4,864.31
3,951.94
3,771.75
3,434.28
3,188.12
EBITDA Margin
20.63%
20.75%
20.15%
14.96%
18.69%
21.53%
21.06%
20.20%
22.91%
23.03%
23.11%
Other Income
548.34
621.85
557.38
290.59
322.58
380.85
191.87
155.32
101.98
115.89
203.80
Interest
400.78
457.24
289.71
140.48
48.64
74.49
305.13
262.60
77.72
66.72
256.70
Depreciation
1,744.05
1,649.42
1,521.66
1,244.58
1,126.52
1,055.39
966.71
667.95
557.97
427.63
392.37
PBT
5,184.57
5,097.98
4,589.01
2,624.17
3,531.96
4,584.37
3,784.34
3,176.71
3,238.04
3,055.82
2,742.85
Tax
1,671.37
1,582.72
1,211.02
684.85
725.63
2,009.77
899.35
726.85
818.27
759.65
720.71
Tax Rate
32.24%
31.05%
27.54%
26.10%
21.32%
27.16%
23.93%
23.53%
25.27%
24.86%
26.28%
PAT
3,513.20
3,485.88
3,172.97
1,927.50
2,648.15
5,334.84
2,845.14
2,364.73
2,423.17
2,301.66
2,025.09
PAT before Minority Interest
3,515.20
3,483.57
3,168.97
1,927.65
2,647.11
5,333.82
2,843.69
2,364.50
2,422.91
2,301.19
2,023.59
Minority Interest
2.00
2.31
4.00
-0.15
1.04
1.02
1.45
0.23
0.26
0.47
1.50
PAT Margin
10.59%
10.99%
10.94%
7.75%
11.29%
21.53%
12.32%
12.09%
14.72%
15.44%
14.68%
PAT Growth
0.37%
9.86%
64.62%
-27.21%
-50.36%
87.51%
20.32%
-2.41%
5.28%
13.66%
 
EPS
60.49
60.02
54.63
33.19
45.59
91.85
48.99
40.72
41.72
39.63
34.87

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
32,653.32
29,842.80
26,839.85
24,575.98
21,929.87
16,824.67
13,890.78
11,680.42
9,371.91
7,287.30
Share Capital
58.08
58.59
58.59
58.59
58.59
58.59
58.59
58.59
58.59
58.52
Total Reserves
32,595.24
29,784.21
26,781.26
24,517.39
21,871.28
16,766.08
13,832.13
11,621.76
9,313.22
7,227.50
Non-Current Liabilities
1,162.74
1,808.94
866.87
903.10
807.27
555.09
358.13
594.11
102.07
583.85
Secured Loans
1,159.38
2,134.90
618.96
249.21
168.49
0.00
48.88
26.96
177.59
380.10
Unsecured Loans
402.27
0.00
0.00
0.00
0.00
0.00
131.07
424.24
3.81
362.71
Long Term Provisions
282.93
225.70
172.72
171.79
157.11
74.71
46.54
55.86
39.13
23.36
Current Liabilities
14,682.34
12,199.13
11,493.78
8,155.98
10,665.05
11,384.64
12,020.57
8,665.89
6,605.60
7,840.22
Trade Payables
4,188.85
4,454.16
3,871.31
2,703.05
2,794.68
2,576.06
2,552.18
2,372.90
2,154.70
2,457.03
Other Current Liabilities
4,623.28
3,161.05
2,979.91
3,106.51
2,684.31
2,874.56
2,510.51
1,967.42
1,286.82
1,577.58
Short Term Borrowings
5,309.72
4,078.12
4,230.43
2,117.83
4,803.78
5,422.30
6,573.21
4,031.34
2,902.72
3,672.68
Short Term Provisions
560.49
505.80
412.13
228.59
382.28
511.72
384.67
294.23
261.36
132.93
Total Liabilities
48,492.01
43,858.87
39,212.50
33,633.13
33,401.31
28,764.54
26,271.07
20,942.24
16,081.66
15,713.92
Net Block
14,794.19
14,492.79
11,023.69
10,532.09
9,373.58
9,396.47
8,474.85
6,520.68
4,833.78
4,179.69
Gross Block
24,462.96
23,447.77
18,593.32
15,943.09
13,613.33
12,441.26
10,497.62
7,894.78
5,635.49
4,569.83
Accumulated Depreciation
9,659.15
8,952.24
7,569.63
5,411.00
4,239.75
3,044.79
2,022.77
1,374.10
801.71
390.14
Non Current Assets
21,329.55
19,653.24
17,666.83
15,510.44
13,577.80
12,352.03
10,938.77
8,764.08
6,875.48
5,419.57
Capital Work in Progress
4,899.96
3,868.72
5,390.01
3,747.20
3,061.53
1,985.92
1,668.46
1,583.04
1,458.08
848.14
Non Current Investment
251.70
321.65
391.74
618.30
431.22
554.69
360.20
311.52
245.85
122.94
Long Term Loans & Adv.
973.42
714.55
794.00
575.33
658.44
378.34
396.64
261.91
256.48
236.56
Other Non Current Assets
410.28
255.53
67.39
37.52
53.03
36.61
38.62
86.93
81.29
32.24
Current Assets
27,162.46
23,771.92
21,459.91
18,043.59
19,739.90
16,412.51
15,332.30
12,178.16
9,206.18
10,294.35
Current Investments
0.01
50.58
151.00
378.85
159.79
0.02
0.02
0.02
0.02
0.02
Inventories
10,543.72
9,808.23
8,511.23
7,553.85
9,026.57
7,699.87
7,245.60
5,858.41
4,330.54
4,056.14
Sundry Debtors
5,745.93
4,816.74
4,466.38
4,012.26
3,503.28
4,315.16
3,413.78
3,080.20
2,765.33
4,606.68
Cash & Bank
8,235.49
6,278.30
6,084.20
4,190.01
5,474.28
2,842.15
1,957.18
1,262.25
513.48
800.26
Other Current Assets
2,637.31
519.45
554.71
393.95
1,575.98
1,555.31
2,715.72
1,977.28
1,596.81
831.25
Short Term Loans & Adv.
1,983.31
2,298.62
1,692.39
1,514.67
1,058.30
1,065.96
795.90
753.96
512.09
366.88
Net Current Assets
12,480.12
11,572.79
9,966.13
9,887.61
9,074.85
5,027.87
3,311.73
3,512.27
2,600.58
2,454.13
Total Assets
48,492.01
43,425.16
39,126.74
33,554.03
33,317.70
28,764.54
26,271.07
20,942.24
16,081.66
15,713.92

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
3,924.62
2,434.52
2,386.75
5,016.48
3,329.05
4,381.28
1,650.97
1,954.52
3,278.58
1,419.76
PBT
5,066.29
4,379.99
2,612.50
3,372.74
7,343.59
3,743.04
3,091.35
3,241.18
3,060.84
2,744.30
Adjustment
1,834.16
1,496.24
1,586.47
1,344.13
-1,662.64
1,091.17
813.95
535.02
408.92
487.50
Changes in Working Capital
-1,244.48
-1,675.07
-1,094.98
1,557.80
-1,066.65
307.91
-1,484.50
-1,123.12
582.52
-1,079.41
Cash after chg. in Working capital
5,655.97
4,201.16
3,103.99
6,274.67
4,614.30
5,142.12
2,420.80
2,653.08
4,052.28
2,152.39
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,731.35
-1,766.64
-717.24
-1,258.19
-1,285.25
-760.84
-769.83
-698.56
-773.70
-732.63
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,875.80
-4,255.95
-3,977.75
-3,211.56
598.69
-1,567.64
-2,902.59
-1,926.59
-1,787.04
-1,445.21
Net Fixed Assets
-141.97
2,277.63
-503.75
1,473.74
-428.03
-760.60
-799.00
-771.00
-1,092.24
125.11
Net Investments
-1,816.13
-5,288.07
-1,521.01
-1,574.43
-2,482.52
-188.35
-371.56
-285.55
-498.60
-170.60
Others
82.30
-1,245.51
-1,952.99
-3,110.87
3,509.24
-618.69
-1,732.03
-870.04
-196.20
-1,399.72
Cash from Financing Activity
119.78
800.42
1,814.41
-2,969.27
-1,364.94
-1,947.18
1,919.06
864.15
-1,915.26
365.44
Net Cash Inflow / Outflow
2,168.60
-1,021.01
223.41
-1,164.35
2,562.80
866.46
667.44
892.08
-423.72
339.99
Opening Cash & Equivalents
3,385.43
4,392.27
4,162.51
5,329.91
2,746.82
1,875.58
1,209.94
318.03
743.49
403.81
Closing Cash & Equivalent
5,563.79
3,385.43
4,392.27
4,162.51
5,329.91
2,746.82
1,875.58
1,209.94
319.63
743.50

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
562.21
509.35
458.10
419.46
374.29
287.16
237.08
199.36
159.96
124.50
ROA
7.54%
7.63%
5.29%
7.90%
17.34%
10.39%
10.00%
13.07%
14.44%
14.13%
ROE
11.15%
11.18%
7.50%
11.38%
27.81%
18.62%
18.47%
22.99%
27.57%
32.51%
ROCE
14.39%
13.76%
9.39%
12.71%
30.33%
18.79%
17.97%
22.72%
24.92%
27.35%
Fixed Asset Turnover
2.65
2.84
2.95
3.24
3.73
4.12
4.36
2.44
2.96
2.79
Receivable days
30.33
28.34
30.42
28.69
29.37
29.85
29.56
64.66
89.16
106.53
Inventory Days
58.44
55.92
57.65
63.29
62.82
57.72
59.64
112.70
101.43
100.27
Payable days
135.14
133.88
117.74
108.60
111.03
53.30
58.56
67.77
75.73
81.70
Cash Conversion Cycle
-46.37
-49.62
-29.67
-16.62
-18.84
34.27
30.63
109.58
114.86
125.10
Total Debt/Equity
0.24
0.21
0.18
0.10
0.23
0.33
0.50
0.41
0.36
0.69
Interest Cover
12.08
16.12
19.60
70.34
100.33
13.32
12.76
42.66
46.80
11.69

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Aurobindo gets nod for Dextromethorphan Polistirex Extended-Release Oral Suspension
    18th Apr 2026, 14:16 PM

    The product will be manufactured at Unit-IV of APL Healthcare, a wholly owned subsidiary of the company, and will be launched in Q2FY27

    Read More
  • Aurobindo Pharma gets USFDA’s final nod for Glycerol Phenylbutyrate Oral Liquid
    17th Apr 2026, 11:12 AM

    The product will be manufactured by Unit-III of the company and will be launched immediately

    Read More
  • Aurobindo Pharma’s arm signs additional product schedule with MSD
    15th Apr 2026, 16:58 PM

    TheraNym will invest around $150 to $175 million for establishing said facility

    Read More
  • Aurobindo Pharma gets USFDA’s final nod for Dapagliflozin tablets
    8th Apr 2026, 14:11 PM

    These products will be manufactured at Unit-IV of APL Healthcare, a wholly owned subsidiary of the company

    Read More
  • Aurobindo Pharma gets final nod for Dapagliflozin, Metformin Hydrochloride Extended-Release Tablets
    8th Apr 2026, 09:50 AM

    These products will be manufactured at unit-IV of APL Healthcare, a wholly owned subsidiary of the Company and will be launched immediately

    Read More
  • Aurobindo Pharma’s arm gets EIR for Telangana unit
    20th Mar 2026, 11:49 AM

    The USFDA has classified the said facility as Voluntary Action Indicated and this inspection is now closed

    Read More
  • Aurobindo Pharma’s arm gets OAI classification from USFDA for Rajasthan unit-II
    18th Mar 2026, 10:10 AM

    At the end of the inspection, a ‘Form 483’ was issued with 09 observations

    Read More
  • Aurobindo Pharma’s arm gets EIR for Unit-IV facility in Andhra Pradesh
    12th Mar 2026, 11:17 AM

    The USFDA has classified the facility as ‘Voluntary Action Indicated’

    Read More
  • Aurobindo Pharma’s arm launches Pomalidomide Capsules in US
    4th Mar 2026, 15:12 PM

    Eugia Pharma Specialities was one of the First-to-File ANDA applicants for this product

    Read More
  • USFDA completes inspection at Aurobindo Pharma’s arm's Formulation facility in Telangana
    27th Feb 2026, 17:44 PM

    The inspection concluded with 4 observations

    Read More
  • Aurobindo Pharma’s arm gets USFDA’s nod to manufacture, market ‘Everolimus Tablets’
    26th Feb 2026, 14:11 PM

    This approval has been received from Eugia Unit-I and is expected to be launched in Q1FY27

    Read More
  • Aurobindo Pharma incorporates wholly owned subsidiary
    25th Feb 2026, 16:44 PM

    The object of incorporation is to expand the contract manufacturing and other pharmaceutical manufacturing operations

    Read More
  • Aurobindo Pharma reports 8% rise in Q3 consolidated net profit
    10th Feb 2026, 11:27 AM

    The consolidated total income of the company increased by 8.58% at Rs 8,833.54 crore for Q3FY26

    Read More
  • Aurobindo Pharma’s arm gets 11 observations from USFDA for Telangana Formulation facility
    7th Feb 2026, 11:47 AM

    The inspection was conducted from January 27 to February 06, 2026

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.